Key Takeaways
- Sanofi has signed a significant autoimmune and immunology development pact with Earendil Labs, a U.S. artificial intelligence research biotech, worth up to $2.56 billion.
- The agreement sees Sanofi offer $160 million to apply Earendil’s discovery platform to multiple bispecific autoimmune and inflammatory disease programs.
- Earendil will receive tiered royalties up to low double-digit percent on sales of any bispecific drug that makes it to market.
- The collaboration follows a similar pact signed in April 2025, where Sanofi handed $125 million to Earendil for the exclusive worldwide rights to a pair of bispecific antibodies.
- Sanofi has been bolstering its autoimmune and immunology pipeline with several significant deals, including a $480 million deal with Nurix and a $1.6 billion agreement with Dren Bio.
Introduction to the Partnership
Sanofi, a French pharmaceutical company, has returned to Earendil Labs, a U.S. artificial intelligence research biotech, for another significant autoimmune and immunology development pact. The latest agreement sees Sanofi offer $160 million, spread between upfront and near-term milestone payments, to apply Earendil’s discovery platform to multiple bispecific autoimmune and inflammatory disease programs. As Earendil CEO Jian Peng, Ph.D., said, "Partnering with Sanofi allows us to apply Earendil’s discovery platform to a broader set of autoimmune disease targets than ever before." This partnership highlights the growing importance of artificial intelligence in the development of next-generation biologics therapeutics.
The Collaboration and Its Terms
The collaboration between Sanofi and Earendil Labs is a significant one, with the potential to bring the deal’s value up to $2.56 billion. Sanofi will take charge of development and worldwide commercialization of all bispecific candidates resulting from the collaboration. In return, Earendil is in line for further development and commercial milestone payments. Additionally, Earendil will receive tiered royalties up to low double-digit percent on sales of any bispecific drug that makes it to market. This partnership is a testament to the strength of Earendil’s discovery platform and its potential to identify and optimize bispecific antibody candidates more efficiently and precisely.
Earendil’s Discovery Platform and Its Potential
Earendil Labs has described itself as a "global leader in AI-driven research and development of next-generation biologics therapeutics." The biotech has developed a discovery platform that combines advanced predictive protein modeling with high-throughput experimental validation. This platform has the potential to identify and optimize bispecific antibody candidates more efficiently and precisely. As Peng added, "By combining advanced predictive protein modeling with high-throughput experimental validation, we can identify and optimize bispecific antibody candidates more efficiently and precisely." This platform has already shown promise, with Earendil announcing the completion of dosing of a first cohort of a phase 1 study of HXN-1001, an anti-TL1A antibody, in July.
Sanofi’s Autoimmune and Immunology Pipeline
Sanofi has been on a spending spree over the past year to bolster its autoimmune and immunology pipeline. The company has signed several significant deals, including a $480 million deal with Nurix for a degrader of a once-undruggable transcription factor and a $1.6 billion agreement with Dren Bio for a CD20-directed antibody aimed at B-cell non-Hodgkin lymphoma. The Paris-based pharma rounded off 2025 by expanding on its relationship with Dren Bio by fronting $100 million to discover and develop a potential next-generation B-cell depleting therapy for "various autoimmune diseases." These deals demonstrate Sanofi’s commitment to advancing next-generation therapeutics that have the potential to set new standards of care.
Conclusion and Future Prospects
The partnership between Sanofi and Earendil Labs is a significant one, with the potential to bring new treatments to patients with autoimmune and inflammatory diseases. As Peng said, "This collaboration underscores our commitment to advancing next-generation therapeutics that have the potential to set new standards of care." With the growing importance of artificial intelligence in the development of next-generation biologics therapeutics, this partnership is a testament to the strength of Earendil’s discovery platform and its potential to identify and optimize bispecific antibody candidates more efficiently and precisely. The future prospects of this partnership are promising, with the potential to bring new treatments to patients and to set new standards of care.
https://www.fiercebiotech.com/biotech/sanofis-latest-autoimmune-bispecific-pact-ai-biotech-could-reach-25b